Tania Jain

Medicine & Life Sciences

1. Chimeric Antigen Receptors 100%
2. Transplantation 74%
3. Primary Myelofibrosis 66%
4. Cell Transplantation 62%
5. Cell- and Tissue-Based Therapy 56%
6. Allogeneic Cells 49%
7. T-Lymphocytes 46%
8. Cytokine Release Syndrome 45%
9. Transplants 40%
10. Survival 40%
11. Cyclophosphamide 38%
12. Bone Marrow 36%
13. Stem Cell Transplantation 35%
14. Graft vs Host Disease 33%
15. Busulfan 30%
16. fludarabine 29%
17. Tissue Donors 29%
18. Myelodysplastic Syndromes 28%
19. Melphalan 26%
20. Therapeutics 25%
21. Acute Myeloid Leukemia 24%
22. Hematopoietic Stem Cell Transplantation 24%
23. Neoplasms 24%
24. Recurrence 23%
25. Confidence Intervals 21%
26. axicabtagene ciloleucel 20%
27. Multiple Myeloma 19%
28. Coronavirus 19%
29. Expert Testimony 18%
30. tocilizumab 17%
31. Homologous Transplantation 16%
32. GS-5734 16%
33. CD19 Antigens 16%
34. Neurotoxicity Syndromes 16%
35. Unrelated Donors 16%
36. B-Cell Lymphoma 16%
37. Mutation 15%
38. Precursor Cell Lymphoblastic Leukemia-Lymphoma 15%
39. Adoptive Immunotherapy 14%
40. Hemophagocytic Lymphohistiocytosis 14%
41. Rituximab 14%
42. Systematic Reviews 13%
43. tisagenlecleucel 13%
44. Meta-Analysis 13%
45. Transplant Recipients 13%
46. Guidelines 12%
47. Incidence 10%
48. SARS Virus 10%
49. Haploidentical Transplantation 10%
50. Bone Marrow Transplantation 9%